100.0% to €2.48 CNWK.DE co.don AG (XETRA) 12 Feb 2026: liquidity test

The CNWK.DE stock moved sharply on 12 Feb 2026, rising 100.00% to €2.48 on XETRA on heavy trading. Volume reached 6,984 versus an average of 9,389, driven by a gap open from €1.20. Traders flagged liquidity and valuation after the jump. We review price action, fundamentals, and what the Meyka AI forecast implies for investors in Germany’s biotech healthcare segment.

CNWK.DE stock: price action and volume

co.don AG (CNWK.DE) opened at €1.20, closed at €2.48, with a session high near €1.28 before the recorded close level. Reported volume was 6,984 shares versus a 50-day average of 9,389, so trading was concentrated but below average. The sharp 100.00% move reflects a large intraday gap and re-rating on XETRA in Germany.

Valuation and income statement metrics

CNWK.DE shows trailing EPS of -0.43 and a negative PE of -5.82. Book value per share is €1.76 and price-to-book is 1.41, signaling a modest premium to equity. Cash per share is €0.78 and current ratio is 3.97, which supports near-term liquidity despite operating losses.

Balance sheet, cash flow and risks

Enterprise value is reported at -€5,224,000, reflecting low market capitalisation and reporting gaps. Debt-to-equity stands at 0.19, and working capital is €8,485,000. Free cash flow per share is -0.86, which highlights ongoing cash burn risk for investors in the biotech development cycle.

Technical context and trading levels

The 50-day average price is €2.47 and the 200-day average is €2.40, placing the close in line with medium-term averages. Year high is €3.49 and year low is €1.20, so upside to the year high is measurable. Traders should note a thin float and lower average volume, increasing short-term volatility.

Meyka AI grade, forecast and price target

Meyka AI rates CNWK.DE with a score out of 100: 62.59 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month target of €3.20, implying 29.03% upside from the current €2.48; forecasts are model-based projections and not guarantees.

Sector backdrop, catalysts and short-term outlook

co.don AG sits in Healthcare, Biotechnology, where peers trade higher average P/E ratios and larger volumes. Catalysts for CNWK.DE include regulatory updates, clinical progress, and contract announcements. Key risks are persistent negative EPS, low free cash flow, and limited liquidity on XETRA. Check the company site for official updates source and the company profile for filings source.

Final Thoughts

CNWK.DE stock posted a headline move, closing at €2.48 after a 100.00% intraday increase on 12 Feb 2026. The jump tested liquidity in a thinly traded name on XETRA, with volume 6,984 versus a 9,389 average. Fundamentals remain mixed: negative EPS (-0.43), solid book value (€1.76) and a healthy current ratio (3.97). Meyka AI’s forecast model projects €3.20 over 12 months, implying 29.03% upside against current levels; forecasts are model-based projections and not guarantees. Our Meyka AI grade of 62.59 (B, HOLD) reflects moderate conviction driven by balance-sheet strength and sector positioning. Short-term traders should prioritise liquidity and stop management. Long-term investors should await clearer clinical or commercial catalysts before increasing exposure to co.don AG on XETRA in Germany.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.